Valsartan significantly reduces mortality and morbidity in heart failure patients but raises safety concerns when combined with an ACE inhibitor and a beta-blocker.
Does valsartan reduce mortality and morbidity in patients with chronic heart failure?
Valsartan improves outcomes in chronic heart failure when added to standard therapy, but triple therapy with an ACE inhibitor and beta-blocker may pose safety concerns.
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
Cohn et al. (2001) studied this question. Valsartan significantly reduces mortality and morbidity in heart failure patients but raises safety concerns when combined with an ACE inhibitor and a beta-blocker.